Gilead Sciences, Inc. GILD NDXSPXR3KPHARMA
Company Overview
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.
Why Investors Should Care
Return on capital employed stands at 21.2%.
Revenue has grown at a 11.4% CAGR over the past five years.
Operating margin of 33.7% supports profitability.
Offers a dividend yield of 2.17%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $29.44B (+2.4% YoY); net profit $8.51B.
- Trailing 12 Months Year-on-year growth — revenue +10.2%, earnings +1672.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 11.4%, profit CAGR 9.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 11.38% |
| 1 Year: | 10.20% |
Compounded Profit Growth
| 5 Years: | 9.79% |
| 1 Year: | 1,672.92% |
Stock Price Performance
| 1 Year: | +34.25% |
| 6 Months: | +19.06% |
| 3 Months: | +22.25% |
| 1 Month: | +3.84% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)60.79 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 21.2%.
- Compounding revenue at 11.4% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GILD Gilead Sciences, Inc. NDXSPXR3KPHARMA | 157.19 | -59.09 | $194.91B | 2.17% | 21.23% | -20.68% | 11.38% | 9.79% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,306.69 | 43.95 | $1.16T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 267.61 | 31.05 | $644.91B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.19 | 80.56 | $503.96B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 424.98 | 27.29 | $381.46B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 147.24 | 117.79 | $363.27B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 156.27 | 23.61 | $297.02B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 172.57 | 25.80 | $267.64B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 676.54 | 36.45 | $250.15B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 5.09B | 5.65B | 5.60B | - | 5.28B | 5.68B | 5.60B | - | 5.55B | 5.14B | 6.58B | - | 6.42B | 6.22B | 7.42B | 6.59B | 6.26B | 7.04B | 6.35B | 6.60B | 7.05B | 6.69B | 6.95B | 7.54B | 6.67B | 7.08B | 7.77B | 6.96B | 7.80B |
| Gross Profit | 7.13B | 7.15B | 7.35B | 6.49B | 6.79B | 6.28B | 6.14B | 5.42B | 5.92B | 5.37B | 4.58B | 4.00B | 4.34B | 4.37B | 4.11B | 4.24B | 4.61B | 4.48B | 4.11B | 4.50B | 4.00B | 5.35B | 5.93B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | 5.62B | 5.58B | - | 4.65B | 4.54B | 4.40B | - | 3.77B | 4.25B | 3.81B | - | 2.15B | 2.28B | 2.62B | - | 2.24B | 2.43B | -1.47B | - | 2.40B | -2.98B | 2.00B | - | 2.89B | 2.25B | 3.84B | 197.00M | 2.03B | 2.84B | 1.71B | 1.67B | 2.62B | -4.32B | 2.64B | 888.00M | 2.24B | 2.47B | 3.33B | 2.59B | -10.39B |
| Net Income | 4.49B | 4.60B | 4.68B | 3.57B | 3.50B | 3.33B | 3.11B | 2.70B | 3.07B | 2.72B | -3.87B | 1.54B | 1.82B | 2.10B | 3.00M | 1.98B | 1.88B | -1.17B | 2.70B | 1.55B | -3.34B | 360.00M | 1.55B | 1.73B | 1.52B | 2.59B | 19.00M | 1.14B | 1.79B | 1.01B | 1.04B | 2.18B | -4.17B | 1.61B | 1.25B | 1.31B | 1.96B | 3.05B | 2.02B | -10.50B |
| Diluted EPS | 2.92 | 3.06 | 3.18 | 2.53 | 2.58 | 2.49 | 2.34 | 2.05 | 2.33 | 2.06 | -2.96 | 1.17 | 1.39 | 1.60 | 0.00 | 1.54 | 1.47 | -0.92 | 2.12 | 1.22 | -2.66 | 0.29 | 1.23 | 1.37 | 1.21 | 2.05 | 0.02 | 0.91 | 1.42 | 0.80 | 0.83 | 1.73 | -3.34 | 1.29 | 1.00 | 1.04 | 1.56 | 2.43 | 1.61 | -8.45 |
| R&D Expense | 818.00M | 743.00M | - | 1.26B | 1.48B | 1.14B | - | 931.00M | 864.00M | 789.00M | - | 937.00M | 1.19B | 939.00M | - | 1.06B | 1.16B | 4.99B | - | 1.10B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.23B | 5.34B | 7.01B | 7.95B | 8.39B | 9.70B | 11.20B | 24.89B | 32.64B | 30.39B | 26.11B | 22.13B | 22.45B | 24.69B | 27.30B | 27.28B | 27.12B | 28.75B | 29.44B |
| Operating Income | 2.16B | 2.68B | 3.53B | 3.96B | 3.79B | 4.01B | 4.52B | 15.27B | 22.19B | 17.63B | 14.12B | 8.20B | 4.29B | 4.07B | 9.92B | 7.33B | 7.61B | 1.66B | 10.02B |
| Net Income | 1.58B | 1.98B | 2.64B | 2.90B | 2.80B | 2.59B | 3.08B | 12.10B | 18.11B | 13.50B | 4.63B | 5.46B | 5.39B | 123.00M | 6.22B | 4.59B | 5.67B | 480.00M | 8.51B |
| Diluted EPS | 1.64 | 2.06 | 2.82 | 1.66 | 1.77 | 1.64 | 1.81 | 7.35 | 11.91 | 9.94 | 3.51 | 4.17 | 4.22 | 0.10 | 4.93 | 3.64 | 4.50 | 0.38 | 6.78 |
| R&D Expense | - | - | - | - | 1.23B | 1.76B | 2.12B | 2.85B | 3.01B | 5.10B | 3.73B | 5.02B | 9.11B | - | - | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 6.94B | 9.70B | 11.59B | 17.30B | 21.24B | 22.58B | 34.66B | 51.72B | 56.98B | 70.28B | 63.67B | 61.63B | 68.41B | 67.95B | 63.17B | 62.12B | 58.99B | 59.02B |
| Total Equity | 2.05B | 3.75B | 4.27B | 6.37B | 5.86B | 6.74B | 9.30B | 11.37B | 15.43B | 18.53B | 18.89B | 20.44B | 21.39B | 22.52B | 18.20B | 21.07B | 21.24B | 22.83B | 19.33B | 22.70B |
| Cash & Equivalents | 816.01M | 968.09M | 1.46B | 1.27B | 907.88M | 9.88B | 1.80B | 2.11B | 10.03B | 12.85B | 8.23B | 7.59B | 17.94B | 11.63B | 6.00B | 5.34B | 5.41B | - | - | - |
| Long Term Debt | - | - | - | - | - | 7.61B | 7.05B | 3.94B | 11.92B | 21.07B | 26.35B | 30.80B | 24.57B | 22.09B | 28.64B | 25.18B | 22.96B | 23.19B | 24.90B | 22.13B |
| Current Liabilities | - | - | 1.22B | 1.87B | 2.46B | 2.51B | 4.24B | 6.41B | 5.76B | 9.89B | 9.22B | 11.63B | 10.61B | 9.76B | 11.40B | 11.61B | 11.24B | 11.28B | 12.00B | 11.81B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 1.67B | 2.14B | 3.08B | 2.83B | 3.64B | 3.19B | 3.10B | 12.82B | 21.25B | 17.05B | 11.90B | 8.40B | 9.14B | 8.17B | 11.38B | 9.07B | 8.01B | 10.83B | 10.02B |
| Investing Cash Flow | -1.30B | -178.82M | -2.22B | -1.94B | 3.59B | -11.85B | -254.00M | -1.82B | -12.47B | -11.98B | -16.07B | 14.36B | -7.82B | -14.62B | -3.13B | -2.47B | -2.27B | -3.45B | -4.79B |
| Financing Cash Flow | -170.98M | -1.47B | -1.05B | -1.34B | 1.76B | 563.00M | -2.54B | -3.02B | -5.88B | -9.72B | 3.39B | -12.32B | -7.63B | 770.00M | -8.88B | -6.47B | -5.12B | -3.43B | -7.75B |
| Capital Expenditure | - | - | - | - | - | - | -134.00M | - | - | - | - | -924.00M | -825.00M | -650.00M | -579.00M | -728.00M | -585.00M | -523.00M | -563.00M |
| Free Cash Flow | - | - | - | - | - | - | 2.97B | - | - | - | - | 7.48B | 8.32B | 7.52B | 10.80B | 8.34B | 7.42B | 10.30B | 9.46B |
| Share Buybacks | 487.54M | 1.97B | 998.50M | 4.02B | 2.38B | 667.00M | 582.00M | 5.35B | 10.00B | 11.00B | 954.00M | 2.90B | 1.75B | 1.58B | 546.00M | 1.40B | 1.00B | 1.15B | 1.92B |
| Dividends Paid | - | - | - | - | - | - | 0 | 0 | 1.87B | 2.46B | 2.73B | 2.97B | 3.22B | 3.45B | 3.60B | 3.71B | 3.81B | 3.92B | 4.00B |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 51.2% | 50.2% | 50.3% | 49.8% | 45.2% | 41.3% | 40.4% | 61.3% | 68.0% | 58.0% | 54.1% | 37.1% | 19.1% | 16.5% | 36.3% | 26.9% | 28.0% | 5.8% | 34.0% |
| Net Margin % | 37.5% | 37.1% | 37.6% | 36.5% | 33.4% | 26.7% | 27.5% | 48.6% | 55.5% | 44.4% | 17.7% | 24.7% | 24.0% | 0.5% | 22.8% | 16.8% | 20.9% | 1.7% | 28.9% |
| ROE % | 42.2% | 46.3% | 41.4% | 49.5% | 41.6% | 27.9% | 27.0% | 78.4% | 97.7% | 71.5% | 22.6% | 25.5% | 23.9% | 0.7% | 29.5% | 21.6% | 24.8% | 2.5% | 37.5% |
| ROCE % | - | 46.9% | 45.1% | 43.4% | 25.6% | 23.6% | 28.0% | 52.8% | 53.1% | 36.9% | 24.1% | 15.5% | 8.3% | 7.1% | 17.6% | 14.1% | 15.0% | 3.5% | 21.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 9.83% | 121.84M | $18.42B |
| 2 | Vanguard Capital Management LLC | 6.54% | 81.09M | $12.26B |
| 3 | FMR, LLC | 5.39% | 66.87M | $10.11B |
| 4 | State Street Corporation | 4.94% | 61.22M | $9.25B |
| 5 | Capital World Investors | 3.31% | 40.99M | $6.20B |
| 6 | Invesco Ltd. | 3.21% | 39.82M | $6.02B |
| 7 | Vanguard Portfolio Management LLC | 2.85% | 35.32M | $5.34B |
| 8 | Geode Capital Management, LLC | 2.42% | 30.07M | $4.55B |
| 9 | Price (T.Rowe) Associates Inc | 2.42% | 30.00M | $4.53B |
| 10 | Morgan Stanley | 1.94% | 24.00M | $3.63B |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GILD
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNc215TTRESFVoSER2WGJmeFNnM1gtR1JSTWM1VU81c2lmTzhtUTNmMDM3dW5KM3dDQUdMUUtiQzM1QjZWeWdMazNVSmE3cjFSZ3NfRGZuY2dwOWJVTW5RWUF3aXBHLXl3R0RuUkhpMzk2MWdGb2cyQjdQdENyUjkxS1JwWFZqdDI3bldhX0…
Gilead agreed to buy an experimental pill that could treat inflammatory bowel disease - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNUXdPWmRGVWtLaWRWSnkyblRaX2NEMzRwRHBqRjVXa2VjUkJra3BXeUN5ZkctWVphdURVZVpDMnFZV2JwT25Va2NqUW5abTU5NnpZWGV5WUFYdUtUbEJWSHVDZVNuRXJrZkU3ZWprSzd0RWlrd3pubVpPNF9oN2VmaS1heFBhNmlEcVpQcV…
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOZzZ3VXhRNWdPaHpLZU9SLUxFZ0V2WTBmSE5LRFVyYllyVkV4YXhyWlh5LWhMMGdUOVZWTEQ1azBYMUVhcEp2Y2k4MzRQR1Y0ZnZZVldsVUtIQ09vYlBpQmRza25WbHBMSDZkRXQ5SlRpVk1Xc3dCMDhrYTZpQWtabTRyMzlXQ1A3VGxoZX…
What Has Changed About Owning Gilead Stock? - Trefis
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOXzVnbTNMbFFrdzNTdXpHZndTRDRBdUJZM1dIcU5Ea2hjSndlY2F1UTlmOTFIcFlLNGJjbUE1X0VKQ1lJbjNwYzcwWkw0WkEyVzdPd2twck4xWjhBTGplUHR5NXFTZjA2WEd0SHZodkxVRkJWcEFXU2M0OFR4Y1B0RjJ5VGZpaGZIS1h5Mn…
Gilead Sciences, Inc. $GILD Stock Sold by Crossmark Global Holdings Inc. - MarketBeat
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxNTmpRdHhjN2l4Y1FPaEFtVkNraHZsaGFXM0haZnAtVUJ0V1dhS1loWTJfMnAxd0txMEJDbWMzRTlqdDFETy04V2NHZDBaRWFtS0RzTHluRFNzbjliak1aS0NSU2cxa1AyaDhGdng3NGtGbnBCc09ZWlVmM1REMGZhR0ZKbWEwN2FnV3pSNz…
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNTHB3N1ZTS1A5ajYxR1dEY0NHYVJlVUxOMmM0akV5eV84N2tWSEJwM1dEUWg3WTZvZnlGSVo3Mk91M2g4Ti1ZbGpSWngxOVc1YldsdUJDZUs5bXpIbFNoYkU5b1dXLU5lNVhRZ3VubF8wLWZURXgwdFBCU2JTdHN1TU5RdUpzSUFkY1hRQn…
GILD — Frequently Asked Questions
What is the current share price of Gilead Sciences, Inc. (GILD)?
As of 2026-10-22 16:30 PDT, Gilead Sciences, Inc. (GILD) trades at $157.19 on NasdaqGS. Its 52-week range is $107.89 to $157.37.
What is the market capitalisation of GILD?
Gilead Sciences, Inc. (GILD) has a market capitalisation of $194.91B on NasdaqGS.
What is the P/E ratio of GILD?
GILD trades at a trailing price-to-earnings (P/E) ratio of -59.09. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 15.75.
Does GILD pay a dividend?
Gilead Sciences, Inc. (GILD) currently offers a dividend yield of 2.17%.
What is the return on equity (ROE) of GILD?
GILD has a return on equity (ROE) of -20.68%. Its return on capital employed (ROCE) is 21.23%.
Is GILD a good stock to buy?
This page provides a data-driven analysis of Gilead Sciences, Inc. (GILD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.